HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].

Abstract
We performed a retrospective study that compared the efficacy and safety of ramosetron with azasetron in a case of acute and delayed emesis induced by cisplatin (CDDP)-included chemotherapy in patients with lung cancer. The study subjects were 100 lung cancer patients treated with combination therapy of cisplatin, ifosfamide, irinotecan (CIC therapy). The ramosetron group and azasetron group received, respectively, ramosetron 0.3 mg or azasetron 10 mg intravenous injection, 30 minutes prior to CDDP. All patients received 32 mg of dexamethasone intravenously. Protection from emesis showed no significant difference between two treatment groups. However, the grade of nausea was significantly lower in the ramosetron group than in the azasetron group. Furthermore, chlorpromazine hydrochloride for use as a rescue medication was required by significantly fewer in the ramosetron group than in the azasetron group. Adverse effects were observed in 27 cases in the ramosetron group and 24 cases in the azasetron group. However, because the symptoms were all mild, we did not consider there was any safety problem. In conclusion, it was suggested that ramosetron is a clinically useful treatment for acute and delayed emesis induced by cisplatin-induced chemotherapy in patients with lung cancer.
AuthorsToru Hayakawa, Mayumi Sato, Masako Konaka, Azusa Makino, Tae Hirohata, Sawako Totsu, Yoshiko Wada, Hideki Sato, Nobuo Inotsume, Akihisa Fujita, Kyu-ichiro Sekine
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 33 Issue 5 Pg. 633-8 (May 2006) ISSN: 0385-0684 [Print] Japan
PMID16685162 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antiemetics
  • Benzimidazoles
  • Bridged Bicyclo Compounds, Heterocyclic
  • Oxazines
  • Irinotecan
  • azasetron
  • ramosetron
  • Cisplatin
  • Ifosfamide
  • Camptothecin
Topics
  • Adult
  • Aged
  • Antiemetics (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)
  • Camptothecin (administration & dosage, analogs & derivatives)
  • Cisplatin (adverse effects)
  • Female
  • Humans
  • Ifosfamide (administration & dosage)
  • Irinotecan
  • Lung Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Nausea (prevention & control)
  • Oxazines (therapeutic use)
  • Retrospective Studies
  • Vomiting, Anticipatory (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: